慢性髓性白血病:2020年诊断、治疗与监测更新
本文综述慢性髓性白血病(CML)的疾病特征、诊断标志及治疗策略。CML以t(9;22)易位形成的BCR-ABL1融合基因为特征,一线可选四种酪氨酸激酶抑制剂(TKI),二代TKI虽反应更深更快但未延长生存。挽救治疗包括二代/三代TKI,T315I突变者仅对帕纳替尼敏感,异基因移植适用于至少两种TKI失败或进展期患者。
要点
- CML诊断依据t(9;22)(q34;q11.2)形成的BCR-ABL1融合基因(费城染色体)。
- 一线TKI包括伊马替尼、尼洛替尼、达沙替尼和博舒替尼。
- T315I突变者对现有TKI耐药,仅帕纳替尼有效。
核心结论
- CML是一种以BCR-ABL1融合基因为特征的骨髓增殖性肿瘤,多种TKI及异基因移植构成其治疗体系。
研究设计与样本
- 本文为综述,纳入CML诊断、一线及挽救治疗与监测相关证据,未报告系统检索范围与样本量。
主要发现
- CML在成人中发病率为每10万成人1-2例,约占成人新诊断白血病的15%。
- 二代TKI临床试验报告了显著更深更快的缓解,但未延长生存,可能归因于一线TKI细胞遗传学复发后高效挽救治疗的存在。
关键数值与推荐
- 美国FDA批准伊马替尼、尼洛替尼、达沙替尼和博舒替尼用于新诊断慢性期CML(CML-CP)的一线治疗。
- 发生T315I「看门人」突变的患者对除帕纳替尼外的所有当前可用TKI均耐药。
- 异基因造血干细胞移植仍是至少2种TKI治疗失败的CML-CP患者及所有进展期患者的重要治疗选择。
临床怎么用
- 根据患者合并症、疾病分期和BCR-ABL1突变状态选择一线或挽救性TKI。
- 对至少2种TKI失败或进展期CML-CP患者考虑异基因造血干细胞移植。
- 对所有TKI失败后细胞遗传学复发的老年患者,可继续每日使用最有效/低毒TKI,联合或不联合非TKI抗CML药物(如羟基脲、高三尖杉酯碱、阿扎胞苷、地西他滨、阿糖胞苷、白消安等)以维持长期生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1-2 cases per 100 000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults. DIAGNOSIS: CML is characterized by a balanced genetic translocation, t(9;22)(q34;q11.2), involving a fusion of the Abelson gene (ABL1) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2. This rearrangement is known as the Philadelphia chromosome. The molecular consequence of this translocation is the generation of a BCR-ABL1 fusion oncogene, which in turn translates into a BCR-ABL oncoprotein. FRONTLINE THERAPY: Four tyrosine kinase inhibitors (TKIs), imatinib, nilotinib, dasatinib, and bosutinib are approved by the United States Food and Drug Administration for first-line treatment of newly diagnosed CML in chronic phase (CML-CP). Clinical trials with second generation TKIs reported significantly deeper and faster responses, but they had no impact on survival prolongation, likely because of the existence of highly effective salvage therapies for patients who have a cytogenetic relapse with frontline TKI. SALVAGE THERAPY: For CML post failure on frontline therapy, second-line options include second and third generation TKIs. Although potent and selective, these exhibit unique pharmacological profiles and response patterns relative to different patient and disease characteristics, such as patients' comorbidities, disease stage, and BCR-ABL1 mutational status. Patients who develop the T315I "gatekeeper" mutation display resistance to all currently available TKIs except ponatinib. Allogeneic stem cell transplantation remains an important therapeutic option for patients with CML-CP who have failed at least 2 TKIs, and for all patients in advanced phase disease. Even among older patients who have a cytogenetic relapse post failure on all TKIs, they can maintain long-term survival if they continue on a daily most effective/less toxic TKI, with or without the addition of non-TKI anti-CML agents (hydroxyurea, omacetaxine, azacitidine, decitabine, cytarabine, busulfan, others).
引用
- Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020. PMID: 32239758. doi:10.1002/ajh.25792
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。